Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system for intrauterine use. It provides hormonal contraception by preventing pregnancy in women of reproductive age, releasing levonorgestrel locally to create an environment that inhibits fertilization and implantation.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this contraceptive device.

Kyleena (levonorgestrel) is a hormonal contraceptive used within the reproductive system to prevent pregnancy. - Contraception (prevention of pregnancy): provides long‑acting reversible birth control for women of childbearing age. - Hormonal intrauterine contraception: delivers continuous low‑dose levonorgestrel directly to the uterine lining for up to five years. - Management of menstrual bleeding: can reduce heavy menstrual bleeding and improve cycle regularity in users.

Common and serious adverse reactions have been reported with Kyleena. Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Breast tenderness - Headache - Mood changes Serious or Rare Side Effects: - Uterine perforation - Device expulsion - Pelvic inflammatory disease - Ectopic pregnancy - Severe allergic reaction (anaphylaxis) - Infection at insertion site

Before using Kyleena, consider the following precautions and warnings. - Pregnancy: contraindicated; product is classified as Pregnancy Category X. - Current pelvic infection: avoid insertion until infection resolved. - History of uterine perforation or abnormal uterine anatomy: requires careful assessment. - Breastfeeding: generally acceptable, but discuss with healthcare provider. - Use of other hormonal contraceptives: may increase hormonal exposure; monitor for side effects. - Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel may interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel levels and contraceptive effectiveness. - Rifampin or other strong CYP3A4 inducers: can decrease hormonal activity of the IUS. - Concurrent use of hormonal therapies that increase estrogen exposure: may raise risk of thromboembolic events. Moderate Interactions (Monitor Closely): - Antifungal agents such as ketoconazole: may increase levonorgestrel concentrations. - St John’s wort (hypericum perforatum): may modestly reduce contraceptive efficacy. - Certain antibiotics (e.g., griseofulvin): may have a mild effect on hormone levels.